Clinical Trials Sponsored by Life Molecular Imaging GmbH

Total 24 results

Life Molecular Imaging GmbH
Life Molecular Imaging SA

Active, not recruiting

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

Alzheimer Disease | Progressive Supranuclear Palsy

Germany
Life Molecular Imaging GmbH

Recruiting

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

Progressive Supranuclear Palsy

Germany
Life Molecular Imaging GmbH
pharmtrace klinische Entwicklung GmbH

Recruiting

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis (CArdiag)

AL Amyloidosis | Cardiac Amyloidosis | ATTR Amyloidosis

United States, Spain, Germany, United Kingdom
Life Molecular Imaging Ltd

Recruiting

[18F]PI-2620 Phase 3 Histopathological Study

Alzheimer Disease

United States
Life Molecular Imaging SA

Terminated

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Prostate Cancer

Austria, Finland
Life Molecular Imaging SA

Completed

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Alzheimer Disease

United States, France, Japan, Australia, Germany
Life Molecular Imaging SA

Completed

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Alzheimer Disease | Amyloid Beta-Protein

Australia
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

Down Syndrome | Amyloid Beta-protein

United States
Life Molecular Imaging SA

Completed

PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers

Diagnostic Imaging

Austria, United States
Life Molecular Imaging SA

Completed

Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers

Diagnostic Imaging

Sweden, Finland
Life Molecular Imaging SA

Terminated

PET Imaging of Intracranial Cancers With 18F-FSPG

Brain Cancer

United States
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

Alzheimer Disease | Amyloid Beta-Protein

United States, Switzerland, Australia, Germany, Japan
Life Molecular Imaging SA

Completed

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations

Diagnostic Imaging

Netherlands, Switzerland
Life Molecular Imaging SA

Completed

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Diagnostic Imaging

Singapore
Life Molecular Imaging SA

Completed

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Neoplasms

United States
Life Molecular Imaging SA

Completed

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Neoplasms | Diagnostic Imaging

Korea, Republic of, United States, Germany
Life Molecular Imaging SA

Completed

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers

Diagnostic Imaging

Switzerland, Finland, Germany
Molecular NeuroImaging
Life Molecular Imaging SA

Completed

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

Alzheimer's Disease (AD) | Progressive Supranuclear Palsy (PSP) | Frontal Temporal Dementia (FTD) | Cortical Basal Syndrome (CBS)

United States
Macquarie University, Australia
Life Molecular Imaging GmbH; Omniscient Neurotechnology

Active, not recruiting

Tau And Connectomics In TES Study (TACIT)

Neurodegenerative Diseases | Cognitive Impairment | Head Injury Trauma | Chronic Traumatic Encephalopathy | Traumatic Encephalopathy

Australia
University of Zurich
Life Molecular Imaging SA

Terminated

Evaluation of a New Imagingtechnologie for Thrombosis (PET-GP1_1)

Deep Vein Thrombosis | Abdominal Aortic Aneurysm

Switzerland
KeifeRx, LLC
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...

Not yet recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Alzheimer Disease
University of Edinburgh
British Heart Foundation; Life Molecular Imaging SA

Completed

18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis

Aortic Valve Disease | Thrombosis Cardiac

United Kingdom
Life Molecular Imaging SA
Walter Reed National Military Medical Center

Active, not recruiting

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

Mild Traumatic Brain Injury

United States
Xuanwu Hospital, Beijing
H. Lundbeck A/S; Hoffmann-La Roche; Genentech, Inc.; Life Molecular Imaging SA; APRINOIA... and other collaborators

Recruiting

A Direct Comparative Study of Tau Tracer in Patients With Alzheimer's Disease (HTH)

Alzheimer Disease

China

Clinical Trials Sponsored by Life Molecular Imaging GmbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations